Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624051 | 0.80 | MIF (0.57) | MIFATML3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL6639561 | 0.80 | MIF (0.34) | MIFLMNACYP2D6 | |
| SCHEMBL11418080 | 0.78 | ALDH1A1 (0.42) | MIFL3MBTL1AOC3CYP2D6 | |
| SCHEMBL5694065 | 0.74 | MIF (0.31) | MIF | |
| SCHEMBL3856003 | 0.73 | MIF (0.44) | MIFKDM4ELMNAAOC3TAAR1 | |
| SCHEMBL6583 | 0.72 | MIF (0.63) | MIFKDM4ELMNACHRM2ADRA1A | |
| SCHEMBL211770 | 0.72 | MIF (0.63) | MIFKDM4ELMNACHRM2ADRA1A | |
| SCHEMBL7980 | 0.72 | MIF (0.63) | MIFKDM4ELMNACHRM2ADRA1A | |
| SCHEMBL23070416 | 0.72 | MIF (0.57) | MIFKDM4ELMNACHRM2ADRA1A | |
| SCHEMBL43325 | 0.72 | SRC (0.42) | MIFL3MBTL1LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960584-B2 | 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-acrylamide; pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane | AMOREPACIFIC CORPORATION (KR) | 2011-06-14 | — | — | US | disclosed |
| US-20080234383-A1 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same | AMOREPACIFIC CORPORATION (KR) | 2008-09-25 | — | — | US | disclosed |
| EP-1861358-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101321-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-28 | — | — | WO | disclosed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234383-A1 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same | TRPV1, TRPA1, TRPV5 | MIF 1740/4885ATM 4701/4885L3MBTL1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.